

# Updates in IOL Technology

Zaina Al-Mohtaseb, MD  
Whitsett Vision Group  
Cataract, Refractive, & Cornea Surgeon  
Director of Research  
Clinical Associate Professor, Baylor College of Medicine  
SEC 2024

# Financial Disclosure

- I have the following financial interests or relationships to disclose:
  - Alcon
  - Zeiss
  - Bausch + Lomb
  - Johnson & Johnson
  - Allergan
  - Visu
  - Vista
  - Ocular Therapeutix
  - Tarsus
  - Dorvue
  - Kala
  - BVI
  - Trefoil
  - CorneaGen
  - Ocuphire

# Introduction

- Increasing expectations
- Cataract surgery now a refractive procedure
- Accuracy, repeatability, and consistency



# Expectations

I choose ONE of the following vision correction options for this eye:  RIGHT  LEFT

1. **Basic cataract surgery with a single-vision lens for best:**

- Distance vision (e.g., driving, watching TV)
- Intermediate vision (e.g., computer, dashboard)
- Near vision (e.g., reading a book)

I realize that I may need to wear glasses or contact lenses even after surgery to get best vision at my preferred choice (listed above) and will certainly require glasses (or contact lenses) to see at the other two distances.


2. **\*Astigmatism correction with either incisions in the cornea or a special lens implant ("toric" lens) and additional procedures (as indicated) to aim for best vision without glasses for:**

- Distance vision (e.g., driving, watching TV)
- Intermediate vision (e.g., computer, dashboard)
- Near vision (e.g., reading a book)

My goal is to have good vision without glasses at my preferred choice (listed above). I understand that I may still require glasses or contact lenses to get my absolute best vision at my preferred distance. In addition, I understand that I will still require glasses or contact lenses to see at other distances.

# Avoid Refractive Errors

- Accurate keratometry & biometry
- Optimize IOL calculations
- Rule out ocular pathology
  - Cornea
  - Retina
- Set appropriate expectations & educate



## Causes and correction of dissatisfaction after implantation of presbyopia-correcting intraocular lenses

This article was published in the following Dove Press journal:  
Clinical Ophthalmology  
11 October 2016  
Number of times this article has been viewed

Allister Gibbons  
Tayyeba K Ali  
Daniel P Warren  
Kendall E Donaldson  
Department of Ophthalmology,  
Bascom Palmer Eye Institute,  
University of Miami Miller School  
of Medicine, Miami, FL, USA

**Purpose:** The purpose of this study was to assess the causes and possible solutions for patient dissatisfaction after the implantation of presbyopia-correcting intraocular lenses (IOLs).

**Methods:** This study was a retrospective review of clinical records. All patients who were seen between January 2009 and December 2013 whose primary reason for consultation was dissatisfaction with visual performance after presbyopia-correcting IOL implantation were included in the study. A single treating physician, who determined the most probable cause of dissatisfaction, decided which interventions to pursue following the initial consultation.

**Results:** Data from 74 eyes of 49 patients were analyzed. The most common cause for complaint was blurry or foggy vision both for distance and near (68%). Complaints were most frequently attributed to residual refractive error (57%) and dry eye (35%). The most common interventions pursued were treatment of refractive error with glasses or contact lenses (46%) and treatment for dry eye (24%). Corneal laser vision correction was done in 8% of eyes; 7% required an IOL exchange. After the interventions, 45% of patients had completed resolution of symptoms, 23% of patients were partially satisfied with the results, and 32% remained completely dissatisfied with the final results.

**Conclusion:** The most identifiable causes of dissatisfaction after presbyopia-correcting IOL implantation are residual refractive error and dry eye. Most patients can be managed with conservative treatment, though a significant number of patients remained unsatisfied despite multiple measures.

**Keywords:** intraocular lens, cataract, presbyopia, multifocal intraocular lens


## Testing

- Refraction
- Topography
- Biometry
- OCT macula

**Measurements of cornea before manipulation or drops applied**

## Testing: Refraction

- Make sure vision commiserate with cataract
- Outcomes of first eye
- Evaluate axis of astigmatism
- Ensure IOL power makes sense
- Posterior corneal astigmatism






## Testing: Topography




## Importance of Topography

- To rule out corneal pathology
  - Ocular surface disease
  - Salzmann's
  - EBMD
  - Fuchs




## Why Does it Matter?

- 77% had corneal staining;
- 63% had decreased TBUT
- Many of these patients were asymptomatic
- Can impact topography and biometry
- Can negatively affect surgical outcomes
  - Decrease goblet cell density, TBUT, & corneal sensitivity



## Screen for Retinal Abnormalities

- ERM
- Macular degeneration
- Drusen
- Results in decreased contrast sensitivity—compounded with multifocals
- Can initially evaluate with IOL Master 700
- Importance of OCT macula for premium expectations










## Near visual acuity

### Binocular UCNVA<sup>1</sup>

- Mean visual acuity J1
- 77.1% J1 or better
- 92.9% J2 or better
- 97.1% J3 or better


### Binocular DCNVA<sup>1</sup>

- Mean visual acuity J1
- 86.0% J1 or better
- 97.7% J2 or better
- 100% J3 or better



## Spectacle independence

### Spectacle Wear at 1 Month




Over 96% of TECNIS Odyssey™ IOL patients did not require spectacles at any distance.<sup>1</sup>

<sup>1</sup>Q: "Was the patient prescribed glasses at the conclusion of the 1-month visit?" Three subjects (3/33) [1 subject for distance, 1 subject for near, and 1 subject for both distance and near]

Johnson & Johnson

1. Data on File (2023) DDF2023CT4061

## Dysphotopsias





Retrospective analysis of reported outcomes, n=96. Three subjects reported severe halo (n=2/96) in both eyes. Two subjects reported severe night glare (n=2/96) in both eyes. For subjects who reported a symptom but did not specify a severity in the chart (8/35), data were classified as mild in the graph above.

**3.1%** Severe halo  
**2.1%** Severe night glare  
**0%** Severe starburst

Majority of symptoms were mild, if present


## Patient Case

- 58 y/o male S/P myopic LASIK OU with cataracts
- Pre Op:
  - OD: Dsc: 20/30 Nsc: J10
  - OS: Dsc: 20/30 Nsc: J6
    - MRX OD: -0.50 + 1.00 X 170
    - MRX OS: -0.75 + 0.25 X 180




# THE LIGHT ADJUSTABLE LENS (LAL)

- Photo-reactive UV absorbing silicone
- Biconvex
- Anterior surface – rounded edge
- Posterior surface – squared edge
- 6-mm diameter



- Blue core polymethylmethacrylate (PMMA) monofilament
- Modified 'C'
- Haptic angle – 10°
- 13mm – LAL total diameter

## LAL METHOD OF ACTION



As the LAL is postoperatively adjusted to deliver customized vision, there are two major differences in the period after cataract surgery

1 Required wear of ultraviolet (UV) protective glasses



2 Completion of light treatments



- 3 treatments
- 2 lock-ins

The RxSight Light Adjustable Lens (LAL) is the world's first adjustable intraocular lens (IOL) that allows office-based optimization of vision after lens implantation and healing

- The LAL delivers excellent outcomes for cataract patients
- Overcomes limitations of both pre-operative and intra-operative prediction processes
- Drives blended vision process without glare and halos
- Niche- post-refractive



Corrects in 0.25D increments of sphere and cylinder

Corrects down to 0.5 diopters of astigmatism

More Patients with Excellent Results	Comparison IOL	Commercial Data LAL <sup>4</sup> (n=121) <sup>a</sup> Distance Eyes
Percent eyes within 0.50 diopter of sphere	74% <sup>1</sup>	93.4%
Percent eyes within 0.50 diopter of cylinder	62-64% <sup>2,3</sup>	90.6%
Percent of eyes 20/20 or better	38-41% <sup>2,3</sup>	80.2%

2x

➔ LAL Patients 2x More Likely to See 20/20

1. Lundstrom M. Changing Practice Patterns in Europe's Cataract Refract Surg. 2011; 47:373-379

2. Tostelloe TR. PMA P980409/0301. FDA Summary of Safety and Effectiveness Data. 2013.

3. AcrySul® Toric P92014/15. FDA Summary of Safety and Effectiveness Data. 2011

4. RxSight PMS-602 Clinical Outcomes of Patients Bilaterally Implanted with LAL.

## SUMMARY

### Refractive Outcomes

- 93.4% within 0.5 D MRSE
- 90.6% within 0.5 D Cylinder
- 2x More LAL Patients See 20/20 UCVA
- 10x Reduced Poor Outcomes (20/40 or worse)

### Dysphotopsia profile

- Due to minimized residual refractive error
- No increased glare or halo, no loss of contrast

### Intermediate/Reading

- Patients select preferred trade-off between distance, intermediate, and near visual acuity
- Symmetrically broadened defocus curve compared to traditional monofocal IOLs
- 80% 20/20 (distance) and J1 (near) possible

1. PMA P92014/15 Clinical Outcomes of Patients Bilaterally Implanted with LAL.

2. Tostelloe TR. PMA P980409/0301. FDA Summary of Safety and Effectiveness Data.

3. PMA P92014/15 Clinical Outcomes of Patients Bilaterally Implanted with LAL.

# Patient Case Outcome


- LAL both eyes implanted
- Post Op: Very happy patient
- OD: Dsc: 20/20 Int: 20/30 Nsc: J5
- OS: Dsc: 20/30 Int: 20/20 Nsc: J2

# LAL Outcomes in Post - Refractive Eyes


## Number of Eyes

- Total: 154
- S/P RK: 56
- Myopic LASIK/PRK: 66 eyes
- Hyperopic LASIK/PRK: 32 eyes


UCVA with LAL IOL in Post RK Eyes (56 eyes)




BCVA with LAL IOL in Post RK Eyes (56 eyes)








Astigmatism with LAL IOL in Eyes with RK (56 eyes)



UCVA with LAL IOL in Post Myopic LASIK/PRK Eyes (66 eyes)








## Patient Case

- 53 year old male with chief complaint of blurry vision in the right eye
- Pre Op:
  - OD: Dsc: 20/80 Nsc: J1
  - OS: Dsc: 20/25 Nsc: J1+
    - MRX OD: -1.75 + 2.75 x 171 20/40
    - MRX OS: -1.50 + 1.25 x 005 20/20






## Aphera™ IOL Wavefront-Filtering Design



The Aphera IOL combines the simple, proven principle of small aperture optics with the quality of an aspheric monofocal IOL.




## Small Aperture Optics



**Large Aperture**  
Equivalent to a monofocal IOL with a 4.0 mm pupil

**Small Aperture**  
~1.36mm




## Wavefront-Filtering technology

The IC-8 Aphera IOL is the first small aperture lens that delivers extended depth of focus through its distinctive wavefront-filtering design.

- EXTENDED DEPTH OF FOCUS, free from "blurry zones"
- EXCELLENT RESULTS REGARDLESS OF ASTIGMATISM in eyes with as much as 1.5 D of corneal astigmatism
- MONOFOCAL-LIKE BINOCULAR CONTRAST SENSITIVITY in bright and low light conditions



BAUSCH + LOMB  
© 2023 Bausch+Lomb APT,0003,USA,23



## Patient Post op





- Aphera implanted in OD
- 1 Week Post Op: Very happy patient
- OD: Dsc: 20/25 Nsc: J1

# Patient Case

- 66 year old female with chief complaint of increasingly blurry vision
- Pre Op:
  - OD: Dsc: 20/200; Dcc: 20/70
  - OS: Dsc: 20/400; Dcc: 20/80
  - With contact lenses; no improvement in refraction


# Exam

PACHYMETRY	511	519
IOP	15	15
PUPILS	No APD	No APD
C/S	White & Quiet	White & Quiet
CORNEA	LASIK Flap, 8 Radials	LASIK Flap, 16 Radials with nasal T cuts
ANTERIOR CHAMBER	Normal Depth, Quiet	Normal Depth, Quiet
LENS	2+ NS, 1+ Cortical	2+ NS, 1+ Cortical
FUNDUS	WNL	WNL



## Post-Op

- Aphthera implanted in OU
- Post Op: happy patient
- OD: Dsc: 20/30
- OS: Dsc: 20/200
  - MRX OD: no improvement
  - MRX OS: -4.00 +6.00 x 075      20/80




Clinical Outcomes of the Small Aperture IOL for Complex Corneas with Irregular Astigmatism

Hasan Alsefiri, BS, Nicole Fram, MD, Elizabeth Yeu, MD, Eric Donnenfeld, MD, Brandon Ayres, MD, Zaina Al-Mohtaseb, Marisa Schoon, MD, Stephen Kwong, BS, Matthew Santos, MD, Emily Rodgers, BS


## Small Aperture IOL: Aphthera/IC-8

- Corrects 1.5 astigmatism
- Non dominant -0.75D-1.00 aim
- 1.36mm aperture
- Pinhole test and pilo test
- Ray tracing simulation of small aperture (Itrace)
- May not correct all of the cylinder but will decrease HOA
- Make sure they dilate to 6.5mm-7.0mm for Nd:YAG posterior capsulotomy



## Methods


- Non-randomized, multicenter retrospective case series of **51 eyes (46 patients)** who received a small aperture IOL in the setting of corneal disease.
- **IOL Master 700 Barrett True K-RK/Post LVC and Barrett True K-Toric (KCN)** with a -0.75 to -1.00 D refractive target were used for planning of IOL power
- **Primary outcomes:** Mean and median absolute errors (AE) and % eyes within 0.50 D, 1.00 D, 1.50D of refractive target were analyzed. Lines of improvement of UCDDVA, BCDVA, UCNVA and BCNVA and Refractive Prediction Error.
- **Secondary outcome measures:** symptomatic dimming requiring explanation, need for scleral lens or topography guided PRK




## Results

Number of Patients	46
Number of Eyes	51
Age, mean ± SD	66.2 ± 7.8 years
Cyl, mean (range)	-1.65 (-5.5 to 0.76)
RK eyes	16
LASIK eyes	14
KCN eyes	14
Other	7


## Uncorrected Distance: 81% are 20/50 or better




### Best Corrected Distance: 75% are 20/30 or better



### Uncorrected Near: 77% are 20/40 or better



### Best Corrected Near: 85% are 20/30 or better




### Visual Acuity/ Lines of Improvement

	Uncorrected Near	Best Corrected Near	Uncorrected Distance	Best Corrected Distance
Baseline	20/62 (0.49)	20/39 (0.29)	20/110 (0.74)	20/46 (0.36)
POM1	20/36 (0.26)	20/25 (0.1)	20/44 (0.34)	20/30 (0.17)
POM3	20/38 (0.28)	20/25 (0.1)	20/38 (0.28)	20/29 (0.16)
Baseline-POM1 (lines improved)	2.6	1.4	6.6	1.6
Baseline-POM3 (lines improved)	2.4	1.4	7.2	1.7
Need for removal due to Dimming	3 patients			

### Conclusions

- UCDVA improved by **7.2 lines** and UCNVA improved by **2.4** at 3 months
- **The off-label** use of the small aperture IOL appears to be safe and effective in patients with corneal pathology (and without central scarring).
- Counsel patients regarding the possibility of dimming
- This technology may offer more **hope for contact lens independence** and better spectacle correction in these complex eyes.



### 65 yold with Restor OU

Vacc	HM	20/40
VA w/ MRX	+10.25 sph 20/20	+0.25 +0.75 x 178 20/20
IOP (central, tonopen)	23	23
Pupils	no apd	No apd
C/S	White and quiet	White and quiet
Cornea	Clear	Clear
Anterior chamber	Vitreous Prolapse	Normal, quiet
Iris	WNL	WNL
Lens	Sunset IOL shifted inferiorly, large anterior capsular opening	Centered PC IOL, PC Intact
Vitreous	WNL	WNL
Fundus exam	WNL	WNL



Thank You

What Questions Do you Have?

**[zaina1225@gmail.com](mailto:zaina1225@gmail.com)**